Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME) With as few as two treatments per year, Susvimo may help people with DME maintain their vision Approval marks the second indication for Susvimo in addition to wet, or neovascular age-related macular [Read More]
Category: Latest News
Current Technology for the Blind and Visually Impaired
Assistive technology for the visually impaired is available from low-tech optical and non-optical aids to electronics and digital technology. Visually impaired and blind individuals have a tremendous number of options to eyesight, depending upon their needs, goals, and financial situations. “Ethyl”, for example, likes to talk on her landline phone. When walking, she uses a [Read More]
Macular Telangiectasia (MacTel)
Prevent Blindness is currently developing new educational materials on macular telangiectasia. We recognize that no one understands the impact of MacTel better than those who are living with it, so we want to hear from you! If you have MacTel and would like to contribute you insight and experiences to help us create effective resources, [Read More]
Genentech to Reintroduce Susvimo for People With Wet AMD
The FDA has approved updates to Susvimo, which will be available to U.S. retina specialists and patients with wet AMD in the coming weeks. Genentech announced today the reintroduction of Susvimo® (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people in the United States with wet, or neovascular, age-related [Read More]
Where Are We Now?
A Summary of the Past 30 Years of Low Vision Research and Development (An update presented to the International Low Vision Support Group by Director Dan Roberts) Macular Degeneration Support’s International Low Vision Support Group will soon celebrate its 30th year as a leading outreach to people affected by macular degeneration and other diseases leading [Read More]